MAVIRET (glecaprevir /pibrentasvir), fixed direct-acting antiviral combination
Reason for request
High clinical benefit for the treatment of chronic hepatitis C virus genotypes 1 to 6 and minor clinical added value compared to other previously available direct-acting antiviral combinations
MAVIRET has been granted a marketing authorisation for the treatment of chronic hepatitis C in adults infected with hepatitis C virus (HCV) genotypes 1 to 6.
Its pan-genotypic virological efficacy is high, with a treatment duration of 8 to 12 weeks for most patients without cirrhosis or with compensated cirrhosis.
Its efficacy has been demonstrated in specific populations such as kidney failure or haemodialysis patients for whom the alternatives are limited.
Its safety and resistance profiles are satisfactory but it has a high medicinal interaction potential.
Improvement in actual benefit